Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28893989 | 1.00 | LMNA (0.54) | LMNAMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL24352194 | 0.88 | TDP1 (0.44) | LMNAMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL28893815 | 0.88 | TDP1 (0.59) | LMNAMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL20424884 | 0.88 | TDP1 (0.59) | LMNAMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL20424885 | 0.88 | TDP1 (0.59) | LMNAMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL24352321 | 0.86 | LMNA (0.58) | LMNAMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL24611339 | 0.86 | TDP1 (0.42) | LMNAMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL28893979 | 0.85 | TDP1 (0.41) | LMNAMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL20441170 | 0.85 | TDP1 (0.41) | LMNAMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL28893883 | 0.85 | TDP1 (0.41) | LMNAMAPTMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710181-A | Compounds for reducing perception of malodour and uses thereof | 凯姆克姆公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20220378675-A1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | CHEMCOM S.A. (BE) | 2022-12-01 | — | — | US | disclosed |
| CN-110494413-B | Compounds for reducing perception of malodour and uses thereof | 凯姆克姆公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4059917-A2 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | ChemCom S.A. (BE) | 2022-09-21 | — | — | EP | disclosed |
| US-11382848-B2 | Compounds reducing malodour perception and the use thereof | CHEMCOM S.A. (BE) | 2022-07-12 | — | — | US | disclosed |
| EP-3573944-B1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | CHEMCOM SA (BE) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382848-B2 | Compounds reducing malodour perception and the use thereof | OR51E2, OR10J3, SRD5A1 | LMNA 4749/4885MAPT 3988/4885MEN1 1364/4885 |
| US-20220378675-A1 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | OR51E2, OR10J3, SRD5A1 | LMNA 4749/4885MAPT 3988/4885MEN1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.